Logo.png
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran
March 27, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, March 27, 2024 (GLOBE NEWSWIRE) -- Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009,...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024 07:05 ET | uniQure Inc.
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...
Logo.png
Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
February 19, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment |...
Logo.png
Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight
February 14, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight   The gene and cell...
market-digits.jpg
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
US Neurologists Opti
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
visiongain Logo.png
Viral Vectors and Plasmid DNA Manufacturing market is projected to grow at a CAGR of 17.5% by 2034: Visiongain
December 19, 2023 12:15 ET | Visiongain Reports Ltd
Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus,...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023 07:05 ET | uniQure Inc.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
sphericalinsightsoptionblue.png
Global Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%
December 15, 2023 05:00 ET | SPHERICAL INSIGHTS LLP
New York, United States , Dec. 15, 2023 (GLOBE NEWSWIRE) -- The Global Gene Therapy Market Size to grow from USD 7.65 Billion in 2022 to USD 49.21 Billion by 2032, at a Compound Annual Growth Rate...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...